Portola Pharmaceuticals (NASDAQ:PTLA) is set to announce its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($1.33) per share for the quarter.
Portola Pharmaceuticals (PTLA) opened at $45.10 on Wednesday. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 12 month low of $28.43 and a 12 month high of $67.10. The stock has a market cap of $2,940.00, a price-to-earnings ratio of -10.44 and a beta of 1.18.
In other news, Director Henry Ward Wolff sold 12,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Portola Pharmaceuticals (PTLA) to Release Quarterly Earnings on Wednesday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/portola-pharmaceuticals-ptla-to-release-quarterly-earnings-on-wednesday.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.